The evolving role of statins in the management of atherosclerosis.

[1]  V. Fuster,et al.  Coronary artery disease: pathogenesis and acute coronary syndromes. , 2001, The Mount Sinai journal of medicine, New York.

[2]  usso,et al.  EFFECT OF HMG-CoA REDUCTASE INHIBITORS ON CORONARY ARTERY DISEASE AS ASSESSED BY ELECTRON-BEAM COMPUTED TOMOGRAPHY , 2000 .

[3]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[4]  OlovWiklund,et al.  Proteoglycans Contribution to Association of Lp(a) and LDL With Smooth Muscle Cell Extracellular Matrix , 1999 .

[5]  T. Callister,et al.  Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. , 1998, The New England journal of medicine.

[6]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[7]  M. Pfeffer,et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.

[8]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[9]  H. White,et al.  Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .

[10]  C. Sirtori,et al.  Direct effects of statins on the vascular wall. , 1998, Journal of cardiovascular pharmacology.

[11]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[12]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[13]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[14]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[15]  B. G. Brown,et al.  Use of niacin, statins, and resins in patients with combined hyperlipidemia. , 1998, The American journal of cardiology.

[16]  N. Delanty,et al.  Vascular effects of statins in stroke. , 1997, Stroke.

[17]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[18]  D. Granger,et al.  Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[20]  T. Saldeen,et al.  Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. , 1997, Journal of the American College of Cardiology.

[21]  K. Ishikawa,et al.  Platelet-dependent thrombin generation in patients with hyperlipidemia. , 1997, Journal of the American College of Cardiology.

[22]  C. Furberg,et al.  Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.

[23]  C. Sirtori,et al.  Platelet α2‐adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine‐induced platelet aggregation , 1997 .

[24]  T. Drake,et al.  Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. , 1997, Circulation research.

[25]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[26]  R. V. van Leeuwen,et al.  Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. , 1997, Biochimica et biophysica acta.

[27]  G. Assmann,et al.  Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. , 1997, Circulation.

[28]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[29]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[30]  SusannaColli,et al.  Vastatins Inhibit Tissue Factor in Cultured Human Macrophages , 1997 .

[31]  H. Wieland,et al.  The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). , 1997, European heart journal.

[32]  P. Ganz,et al.  Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. , 1997, Circulation.

[33]  P. Tsao,et al.  Arginine: a new therapy for atherosclerosis? , 1997, Circulation.

[34]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[35]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[36]  C. Sirtori,et al.  Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. , 1997, Clinical pharmacology and therapeutics.

[37]  J. Willerson.  Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. , 1996, Circulation.

[38]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[39]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[40]  P. Stone,et al.  Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and Normal Cholesterol Levels , 1996, Annals of Internal Medicine.

[41]  H. Crijns,et al.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. , 1996, Circulation.

[42]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[43]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[44]  B. G. Brown,et al.  Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). , 1995, JAMA.

[45]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[46]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[47]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[48]  G. Rogler,et al.  Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro , 1995 .

[49]  H. Amthauer,et al.  Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. , 1995, The American journal of cardiology.

[50]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[51]  A. Simon,et al.  Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[52]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[53]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[54]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[55]  G. Davı̀,et al.  Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[56]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[57]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). , 1995, The American journal of cardiology.

[58]  G. Rogler,et al.  Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. , 1995, The American journal of cardiology.

[59]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[60]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[61]  T. W. Allen.  Effect of simvastatin on coronary atheroma , 1994 .

[62]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[63]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[64]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[65]  S. Milstien,et al.  Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. , 1994, The Journal of clinical investigation.

[66]  James P. Martucci,et al.  Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. , 1994, Circulation.

[67]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[68]  J. Staessen,et al.  Influence of cholesterol lowering on plasma membrane lipids and cationic transport system , 1994, Journal of hypertension.

[69]  L. Wilkins,et al.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.

[70]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[71]  Koji Suzuki,et al.  Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia , 1993, American journal of hematology.

[72]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[73]  M. Ferguson,et al.  Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. , 1993, The Journal of clinical investigation.

[74]  K. Messmer,et al.  Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[75]  F. Parhami,et al.  Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. , 1993, The Journal of clinical investigation.

[76]  J. Albers,et al.  Lipid Lowering and Plaque Regression New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease , 1993, Circulation.

[77]  M. Davies,et al.  Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.

[78]  A. Simon,et al.  Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients. , 1992, Atherosclerosis.

[79]  U. Cogan,et al.  Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. , 1992, Metabolism: clinical and experimental.

[80]  G. Bokoch,et al.  Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. , 1992, The Journal of clinical investigation.

[81]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[82]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[83]  V. Fuster,et al.  Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[84]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[85]  A. Hall,et al.  The cellular functions of small GTP-binding proteins. , 1990, Science.

[86]  M. Weintraub,et al.  HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. , 1989, Circulation.

[87]  G. V. R. Born,et al.  INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES , 1989, The Lancet.

[88]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[89]  D. Steinberg,et al.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[91]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[92]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[93]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[94]  M. Brown,et al.  Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. , 1980, Journal of lipid research.